《内分泌系统疾病》13、糖尿病药物治疗-教学课件（非AI生成）.ppt

DISCUSSIONSummariseallpoints*ChangeinHbA1cFromBaseline(FASPopulation)MeanchangeinHbA1cfrombaselineatweek18,theprimaryefficacyendpoint,wasevaluatedfortheFASpopulation.Treatmentwithsitagliptin100mg/dayresultedinsignificantreductions(–0.7%)inleast-squaresmeanHbA1cchangefrombaselinecomparedwithplacebo(0.3%;P0.001).Theleast-squaresmeanplacebo-subtractedchangeatweek18was–1.0%forthesitagliptintreatmentgroup(95%confidenceinterval,–1.2to–0.8).1Additionally,asignificantlygreaterproportionofpatientsreceivingsitagliptinachievedanHbA1cgoalof7%(P0.001).Specifically,70of339patientsreceivingsitagliptin(20.6%)reachedtheHbA1cgoalcomparedwithonly9ofthe169patientsreceivingplacebo(5.3%).11/Mohanp.109,C1,P2,L1-3;

p.109,C2,P1,L1-5;p.110,C1,Pcont,

L1-4;p.111,Table2

p.112,Fig3AReference1. MohanV,YangW,SonH-Y,etal.Efficacyandsafetyofsitagliptininthetreatmentofpatientswithtype2diabetesinChina,India,andKorea.DiabetesResClinPract.2009;83:106–116.1/Mohanp.109,C1,P2,L1-3;

p.109,C2,P1,L1-5;p.110,C1,Pcont,

L1-4;p.111,Table2

p.112,Fig3A*HbA1c大幅度降低与高HbA1c基线水平相关–52周PostHoc分析在对于HbA1c数据的posthoc分析发现,西格列汀与二甲双胍联合治疗与磺酰脲类（格列吡嗪）联合二甲双胍治疗所有亚组均可降低HbA1c水平.1其中在基线HbA1c≥9%的患者中可见最大降低效应1R.1-p201-F2BR.1-p198-Col2Par.Last-L1-L3p199-Col1Par.Cont-L1-L6Reference1. NauckMA,MeiningerG,ShengD,etal,fortheSitagliptinStudy024Group.Efficacyandsafetyofthedipeptidylpeptidase-4inhibitor,sitagliptin,comparedwiththesulfonylurea,glipizide,inpatientswithtype2diabetesinadequatelycontrolledonmetforminalone:arandomized,double-blind,non-inferioritytrial.DiabetesObesMetab.2007;9:194–205.*胰腺的免疫组化分析：小鼠接收11星期安慰剂或des-F-sitagliptinat0.1,0.4,and1.1%(相应西格列汀43,208and576mg/kg喂养).小鼠的胰腺经过超冻处理，并用HE、抗胰岛素抗体、抗胰高血糖素抗体染色。这里显示的是每组有代表性的胰腺，有各种单个染色以及抗胰岛素/抗胰高血糖素抗体重叠染色。在11个星期时，可以观察到